Trial Profile

Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg plus 500mg loading regimen and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 May 2019 Status changed from active, no longer recruiting to completed.
22 Apr 2019 The trial has been completed in Belgium, Czech Republic and Hungary.
08 Feb 2019 Planned End Date changed from 2 Jan 2019 to 2 Jan 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com